Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio

Leukemia. 2019 Feb;33(2):527-531. doi: 10.1038/s41375-018-0258-y. Epub 2018 Sep 26.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers / blood*
  • Combined Modality Therapy
  • Female
  • Follow-Up Studies
  • Humans
  • Immunoglobulin Light Chains / blood*
  • Immunoglobulin Light-chain Amyloidosis / blood*
  • Immunoglobulin Light-chain Amyloidosis / therapy
  • Male
  • Middle Aged
  • Prognosis
  • Retrospective Studies
  • Survival Rate

Substances

  • Biomarkers
  • Immunoglobulin Light Chains